Beta Bionics (BBNX) began trading on the Nasdaq on Thur 30 Jan 25

Beta Bionics is a diabetes technology company. Its iLet Bionic Pancreas is an automated insulin delivery system that received FDA clearance in 2023 for people with Type 1 diabetes. 

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 279
• Founded by Edward R. Damiano in 2015 
• Headquartered in Irvine, California
• https://www.betabionics.com

Completed its initial public offering (IPO) on January 30, 2025. 

The IPO raised $234.6 million 

Ticker: BBNX

IPO details

• The IPO was for 13,800,000 shares of common stock at $17 per share 
• The underwriters had the option to purchase an additional 1,800,000 shares 
• Beta Bionics also sold 1,000,000 shares in a private placement to an existing investor at $17 per share 
• BofA Securities, Piper Sandler, and Leerink Partners were the lead bookrunners for the offering